---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-013590"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:55:12.096267+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lyell Q1 net loss widens to $68.1M; cash $838M; LYL797 trial starts

## Summary
- GAAP net loss $68.1M vs $55.0M YoY; non-GAAP net loss $50.0M vs $32.3M.
- Cash, equivalents and marketable securities $838M as of March 31, 2022.
- Phase 1 screening started for LYL797 (ROR1 CAR-T) in TNBC/NSCLC; initial data in 2023.
- IND cleared for LYL132 (TCR therapy targeting NY-ESO-1); LYL845 TIL IND on track for H2 2022.
- Appointed Gary Lee, Ph.D., as Chief Scientific Officer to lead research strategy.

## SEC filing metadata
- accession: 0001628280-22-013590
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828022013590/0001628280-22-013590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828022013590/lyel-20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-013590
- JSON: https://secwatch.observer/filing/0001628280-22-013590.json
- Plain text: https://secwatch.observer/filing/0001628280-22-013590.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.